Visiongain has published a new report on Alzheimer’s Drugs Market Report to 2031: Forecasts by Drugs (Donepezil, Rivastigmine, Galantamine, and Memantine), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and e-Commerce) PLUS COVID-19 Recovery Scenarios.

COVID-19 Impact on Alzheimer’s Drugs Market

The COVID-19 pandemic has deleteriously affected all the countries and industries. Similarly, the Alzheimer’s drug market is anticipated to take a hit. The target industry is now facing challenges to manage the interrupted demand and supply of components. Also, unpredictable, and disturbing supply chain activities and the unavailability of human resources are anticipated to impact the target industry growth. In contrast, the rising research & development activities for developing novel treatments against COVID-19 is creating a lucrative opportunity for the companies. Hence, the overall COVID-19 impact is expected to continue to moderate for the global key players operating in the industry.

Download Exclusive Sample of Report @https://www.visiongain.com/report/alzheimers-drugs-market/#download_sampe_div

How the Alzheimer’s Drugs Market report helps you
In summary, our 500+ page report provides you with the following knowledge:

• Revenue forecasts to 2031 for Alzheimer’s Drugs Market, with forecasts for Drug Type and Distribution Channel, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues

• Revenue forecasts to 2031 for 5 regional and 16 key national markets – See forecasts for the Alzheimer’s Drugs market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Argentina, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Alzheimer’s Drugs Market.

Competitive Landscape

Key players operating in the global Alzheimer’s Drugs market are Pfizer, Inc., Lundbeck A/S, Novartis International AG, Hoffman-La Roche Ltd., Janssen Pharmaceutical, TauRx Pharmaceuticals Ltd, Eisai Co. Ltd., and Teva Pharmaceuticals Industries Ltd., VTV Therapeutics, Eli Lilly and Company, AstraZeneca plc, and AC Immune.

The key players have adopted new product development, product launches, product approval, agreement, partnerships, and merger as its key business development strategies to tap into the global Alzheimer’s Drugs market. For instance, on 21st October 2020, Biogen Inc. received the U.S. Food and Drug Administration authorization for aducanumab - Alzheimer's drug. The company filed its application for the drugs to the other regulatory bodies as well includes Europe and Japan. The company will soon launch its drug after getting international approval.

Growing Incidence of Alzheimer’s Disease

The growing occurrence and prevalence of Alzheimer’s disease globally are anticipated to propel the growth of Alzheimer’s drug market. Growing age and the elderly population are at a high risk to develop Alzheimer's disease, which raises the disease occurrence and offers growth opportunities for Alzheimer’s drug market. According to World Population Prospects (WPP) published in 2017 by the United Nations, around 962 million people over age 60, which is estimated for 13% of the worldwide population is anticipated to reach approximately 1.4 billion by 2030, rising at an annual rate of 3%.

Currently, Europe has the highest old population accounting for 25% of the population, the Asia Pacific had an elderly people of 547 million people, and it is likely to reach around 900 million by 2025, therefore these regions have potential opportunities for the target market. For the case, India has over 1 million cases of Alzheimer’s disease yearly. The vigorous healthcare infrastructure and rising healthcare spending in the region and positions it as a key market for Alzheimer’s disease.

Get Detailed TOC @https://www.visiongain.com/report/alzheimers-drugs-market/#download_sampe_div

Many Undiagnosed People and Revised Diagnostic Guidelines

People affected by the initial stages of Alzheimer’s disease with dementia do not have suitable access to the diagnostic center to identify and treat the disease. According to the World Alzheimer Report, only about 50% of people suffering from Alzheimer’s disease undergo diagnosis. The degree of underdiagnoses is about 10% in developing economies, hence, it is likely to boost the Alzheimer’s drug market growth in the forecasted period. Presently, there is no healing treatment existing for Alzheimer’s disease. Though, drugs for Alzheimer’s treatment are in pipeline, which is anticipated to introduce in the coming years, which in turn, is expected to attain a significant growth rate to the target industry during the forecast period.

Market Opportunities

Developments in Techniques for Diagnosis expand Outlook of Target Industry
The developments in techniques for diagnosis, especially by using state-of-the-art PET neuroimaging and cerebrospinal fluid biomarkers have extended the growth projections of the Alzheimer’s drug market. The huge health burden that Alzheimer's disease stances have also reserved the drug pipeline prepared with prospects for the companies, particularly in emerging countries. Their governments to decrease the health burden of Alzheimer's disease have progressively sustained this. Many companies in developed countries such as the U.S. and Europe have been targeting neurodegenerative trails to develop novel therapies against dementia.

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

To access the data contained in this document please email [email protected]

About Visiongain

Visiongain is one of the fastest growing and most innovative, independent, market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10-year forecast, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defense, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports means that you can have a bespoke piece of market intelligence customized to your very own business needs.
-
SOURCE Visiongain Limited.